MARKET

KRTX

KRTX

Karuna Therapeutics
NASDAQ
236.82
+6.84
+2.97%
After Hours: 237.03 +0.21 +0.09% 17:48 12/02 EST
OPEN
229.09
PREV CLOSE
229.98
HIGH
238.67
LOW
229.00
VOLUME
304.35K
TURNOVER
0
52 WEEK HIGH
278.25
52 WEEK LOW
92.26
MARKET CAP
8.14B
P/E (TTM)
-31.8041
1D
5D
1M
3M
1Y
5Y
Insider Sell: Karuna Therapeutics
Insider Sell: Karuna Therapeutics
MT Newswires · 2d ago
--Oppenheimer Adjusts Karuna Therapeutics Price Target to $280 From $285, Maintains Outperform Rating
--Oppenheimer Adjusts Karuna Therapeutics Price Target to $280 From $285, Maintains Outperform Rating
MT Newswires · 11/07 09:28
Earnings Update: Karuna Therapeutics, Inc. (NASDAQ:KRTX) Just Reported And Analysts Are Boosting Their Estimates
Karuna Therapeutics, Inc. ( NASDAQ:KRTX ) just released its latest third-quarter report and things are not looking...
Simply Wall St. · 11/06 12:30
Wells Fargo Maintains Overweight on Karuna Therapeutics, Lowers Price Target to $262
Benzinga · 11/04 16:18
--RBC Cuts Price Target on Karuna Therapeutics to $286 From $293, Maintains Outperform, Speculative Risk Rating
--RBC Cuts Price Target on Karuna Therapeutics to $286 From $293, Maintains Outperform, Speculative Risk Rating
MT Newswires · 11/04 08:32
Karuna Therapeutics GAAP EPS of -$2.38 misses by $0.27
Seekingalpha · 11/03 13:16
Karuna Therapeutics: Q3 Earnings Insights
Benzinga · 11/03 12:52
Karuna Therapeutics, Inc. (KRTX) Reports Q3 Loss, Misses Revenue Estimates
Karuna Therapeutics, Inc. (KRTX) delivered earnings and revenue surprises of -19.60% and 99.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/03 11:55
More
About KRTX
Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Webull offers kinds of Karuna Therapeutics Inc stock information, including NASDAQ:KRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KRTX stock methods without spending real money on the virtual paper trading platform.